Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amphotericin B fat emulsion refers to a pharmaceutical formulation where the antifungal drug Amphotericin B is incorporated into a lipid emulsion, often using commercially available intravenous lipid emulsions like Intralipid (which contains soybean oil, egg phospholipids, and glycerol). Amphotericin B is a polyene antifungal derived from *Streptomyces nodosus*. Its mechanism of action involves binding to ergosterol, a sterol component in the fungal cell membrane, leading to the formation of pores, leakage of essential ions, and ultimately fungal cell death. This fat emulsion formulation aims to reduce the significant toxicity, particularly nephrotoxicity and infusion-related reactions, associated with the conventional amphotericin B deoxycholate formulation, while maintaining its antifungal efficacy. It is typically administered intravenously.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Amphotericin B fat emulsion.